An early genetic diagnosis of neonatal diabetes mellitus is highly beneficial because early switch from insulin to sulfonylurea is safe, avoids unnecessary insulin therapy and promotes sustained improvement of glycaemic control on long-term follow-up
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Mutations in the KCNJ11 gene, which encodes the Kir6.2 subunit of the ATP-sensitive potassium channel, often result in neonatal diabetes.
📊
Key Findings & Data:In this report, we describe a 10-year-old girl who is heterozygous for a new missense mutation in the KCNJ11 gene and whose treatment was successfully switched from insulin to sulfonylurea (glibenclamide) therapy when she was one month old. 10-year data on a low-dose of glibenclamide monotherapy showed excellent glycaemic control with no reports of severe hypoglycaemia and microvascular complications.
💡
Conclusion & Impact:An early genetic diagnosis of neonatal diabetes mellitus is highly beneficial because early switch from insulin to sulfonylurea is safe, avoids unnecessary insulin therapy and promotes sustained improvement of glycaemic control on long-term follow-up
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Background. Mutations in the KCNJ11 gene, which encodes the Kir6.2 subunit of the ATP-sensitive potassium channel, often result in neonatal diabetes. Case. In this report, we describe a 10-year-old girl who is heterozygous for a new missense mutation in the KCNJ11 gene and whose treatment was successfully switched from insulin to sulfonylurea (glibenclamide) therapy when she was one month old. 10-year data on a low-dose of glibenclamide monotherapy showed excellent glycaemic control with no reports of severe hypoglycaemia and microvascular complications. Conclusion. An early genetic diagnosis of neonatal diabetes mellitus is highly beneficial because early switch from insulin to sulfonylurea is safe, avoids unnecessary insulin therapy and promotes sustained improvement of glycaemic control on long-term follow-up
🔖
Cite This Article
JESIC, M. D., STOCK, H., KOVACEVIC, S., SAVIC, M., İ, M. M. J., ZDRAVKOVIC, V. (2021). Neonatal diabetes mellitus due to a new KCNJ11 mutation - 10 years of the patient’s follow-up. Turkish Journal of Pediatrics, Cilt: 63 - Sayı: 3, 490–494. https://ajindex.com/articles/411781
Sperling MA. ATP-sensitive potassium channels – neonatal diabetes mellitus and beyond. N Engl J Med 2006; 355: 507-510
Aydin BK, Bundak R, Bas F, et al. Permanent neonatal diabetes mellitus: same mutation, different glycaemic control with sulfonylurea therapy on long-term follow up. J Clin Res Pediatr Endocrinol 2012; 4: 107-110
Klupa T, Skupien J, Mirkiewicz-Sieradzka B, et al. Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up. Diabetes Technol Ther 2010; 12: 387-391
Vendramini MF, Gurgel LC, Moises RS. Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene. Arq Bras Endocrinol Metabol 2010; 54: 682-684
Iafusco D, Bizzarri C, Cadario F, et al. No beta cell desensitization after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes. Diabetologia 2011; 54: 2736-2738
Ješić MM, Ješić MD, Maglajlić S, Sajić S, Necić S. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation. Diabetes Res Clin Pract 2011; 91: e1-e3
Dahl A, Kumar A. Recent advances in neonatal diabetes. Diabetes Metab Syndr Obes 2020; 13: 355- 364
Lemelman MB, Letourneau L, Greely SAW. Neonatal diabetes mellitus: an update on diagnosis and management. Clin Perinatol 2018; 45: 41-59
De Franco E, Ellard S. Genome, exome, and targeted next-generation sequencing in neonatal diabetes. Pediatr Clin North Am 2015; 62: 1037-1053
Hattersley AT, Greeley SAW, Polak M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2018; 19(Suppl 27): 47-63
Letourneau LR, Carmody D, Wroblewski K, et al. Diabetes presentation in infancy: high risk of diabetic ketoacidosis. Diabetes Care 2017; 40: e147-e148
Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 2004; 89: 5504-5507
Pearson ER, Flechtner I, Njolstad PR, et al; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir 6.2 mutations. N Engl J Med 2006; 355: 467-477
Li X, Xu A, Sheng H, et al. Early transition from insulin to sulfonylureas in neonatal diabetes and follow-up: experience from Ch